Search results for "Sclerosis"

showing 10 items of 1583 documents

Identification of Novel microRNA Profiles Dysregulated in Plasma and Tissue of Abdominal Aortic Aneurysm Patients

2020

microRNAs (miRNAs) are small RNAs that regulate different biological processes. Our objective was to identify miRNAs dysregulated in plasma and tissue of patients with abdominal aortic aneurysm (AAA) and explore new potential targets involved in AAA. Fifty-seven subjects were recruited for a plasma study (30 AAA patients, 16 healthy volunteers and 11 patients with atherosclerosis). The expression level of 179 miRNAs was screened in plasma from a subset of samples, and dysregulated miRNAs were validated in the entire study population. Dysregulated miRNAs were also quantified in aortic tissue of 21 AAA patients and 8 organ donors. Applying a gene set enrichment analysis, an interaction map of…

Male0301 basic medicinePathologymedicine.medical_specialty030204 cardiovascular system & hematologyArticleCatalysisInorganic Chemistrylcsh:Chemistry03 medical and health sciences0302 clinical medicineabdominal aortic aneurysmmicroRNAHealthy volunteersAortic tissuemedicineHumansPhysical and Theoretical ChemistryMolecular BiologyGenelcsh:QH301-705.5SpectroscopyAgedbusiness.industryVascular diseaseGene Expression ProfilingOrganic Chemistrybiomarkersvascular diseaseGeneral MedicineMiddle AgedAtherosclerosismedicine.diseaseAbdominal aortic aneurysmComputer Science ApplicationsmicroRNAs030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Case-Control StudiesmiRNAsPopulation studyFemalebusinessThrombospondin-2Aortic Aneurysm AbdominalInternational Journal of Molecular Sciences
researchProduct

Lipidomic profiling identifies signatures of metabolic risk

2020

Background: Metabolic syndrome (MetS), the clustering of metabolic risk factors, is associated with cardiovascular disease risk. We sought to determine if dysregulation of the lipidome may contribute to metabolic risk factors. Methods: We measured 154 circulating lipid species in 658 participants from the Framingham Heart Study (FHS) using liquid chromatography-tandem mass spectrometry and tested for associations with obesity, dysglycemia, and dyslipidemia. Independent external validation was sought in three independent cohorts. Follow-up data from the FHS were used to test for lipid metabolites associated with longitudinal changes in metabolic risk factors. Results: Thirty-nine lipids were…

Male0301 basic medicineResearch paperdhSL dihydrosphingolipidBMI body mass indexlcsh:MedicineATHEROGENIC LIPOPROTEINSBioinformaticsFHS Framingham Heart StudyPC phosphatidylcholinePESA Progression of Early Subclinical Atherosclerosis0302 clinical medicineFramingham Heart StudyRisk FactorsSAFHS San Antonio Family Heart StudyLC-MS/MS liquid chromatography-tandem mass spectrometryMedicineLongitudinal StudiesMetabolic riskPLASMA SPHINGOLIPID METABOLISMPOPULATIONlcsh:R5-920education.field_of_studySPHINGOMYELINCE cholesteryl esterDysglycemiaGeneral MedicineMiddle AgedLipidomePS phosphatidylserineCardiovascular diseaseLipidsMetabolic syndrome3. Good healthCARDIOVASCULAR-DISEASE030220 oncology & carcinogenesisHEARTMetS metabolic syndromeFemaleDisease SusceptibilityLGPL lysoglycerophospholipidSL sphingolipidlcsh:Medicine (General)LPE lysophosphatidylethanolamineAdultFDR false discovery rateTAG triacylglycerolPopulationCer ceramideCVD cardiovascular diseasePE phosphatidylethanolamineDENSITY-LIPOPROTEINRisk AssessmentGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesAnimalsHumanseducationT2DM type II diabetes mellitusAgedLPC lysophosphatidylcholineSM sphingomyelinbusiness.industryCERAMIDElcsh:RHDL-C High density lipoprotein cholesterolBiomarkerLipid Metabolismmedicine.diseaseObesitySphingolipidCross-Sectional Studies030104 developmental biologyDyslipidemiaERF Erasmus Family StudyLipidomicsMetabolic syndromeINDUCED INSULIN-RESISTANCEbusinessDAG diacylglycerolBody mass indexBiomarkersDyslipidemiaMRM multiple reaction monitoringFASTING GLUCOSE
researchProduct

Genetic investigation of amyotrophic lateral sclerosis patients in south Italy: a two-decade analysis

2020

Amyotrophic lateral sclerosis (ALS) is a multifactorial disease characterized by the interplay of genetic and environmental factors. In the majority of cases, ALS is sporadic, whereas familial forms occur in less than 10% of patients. Herein, we present the results of molecular analyses performed in a large cohort of Italian ALS patients, focusing on novel and already described variations in ALS-linked genes. Our analysis revealed that more than 10% of tested patients carried a mutation in one of the major ALS genes, with C9orf72 hexanucleotide expansion being the most common mutation. In addition, our study confirmed a significant association between ALS patients carrying the ATNX-1 interm…

Male0301 basic medicineSanger sequencingAgingTime FactorsDiseaseCohort Studies03 medical and health sciencessymbols.namesake0302 clinical medicineRisk FactorsC9orf72HumansMedicineAmyotrophic lateral sclerosisRisk factorGenePathologicalAtaxin-1Genetic Association StudiesAmyotrophic lateral sclerosiSanger sequencingGeneticsDNA Repeat ExpansionC9orf72 ProteinMolecular analysibusiness.industryMolecular analysisGeneral NeuroscienceGenetic VariationAmyotrophic lateral sclerosismedicine.disease030104 developmental biologyItalyMutation (genetic algorithm)symbolsFemaleNeurology (clinical)Geriatrics and Gerontologybusiness030217 neurology & neurosurgeryDevelopmental BiologyNeurobiology of Aging
researchProduct

Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hy…

2016

Cholesterol-lowering therapy has been related with several beneficial effects; however, its influence on oxidative stress and endothelial function is not fully elucidated.To investigate the effect of simvastatin and ezetimibe on mitochondrial function and leukocyte-endothelium interactions in polymorphonuclear cells of hyperlipidemic patients.Thirty-nine hyperlipidemic patients were randomly assigned to one of two groups: one received simvastatin (40 mg/day) and the other received ezetimibe (10 mg/day) for 4 weeks, after which both groups were administered combined therapy for an additional 4-week period. Lipid profile, mitochondrial parameters (oxygen consumption, reactive oxygen species (…

Male0301 basic medicineSimvastatinTime FactorsEzetimibe Simvastatin Drug Combination030204 cardiovascular system & hematologyPharmacologymedicine.disease_causechemistry.chemical_compound0302 clinical medicineLeukocytesCells CulturedMembrane Potential Mitochondrialchemistry.chemical_classificationmedicine.diagnostic_testAnticholesteremic AgentsMiddle AgedMitochondriaEndothelial stem cellCholesterolTreatment Outcomemedicine.anatomical_structureFemaleCardiology and Cardiovascular Medicinemedicine.drugEndotheliumAtherosclerosis Ezetimibe Hypercholesterolemia Leukocyte/endothelium interaction Mitochondria Oxidative stress SimvastatinHypercholesterolemiamacromolecular substances03 medical and health sciencesEzetimibeCell AdhesionmedicineHumansAgedReactive oxygen speciesCholesterolbusiness.industryEndothelial CellsEzetimibeCoculture TechniquesOxidative Stress030104 developmental biologychemistrySpainSimvastatinLipid profilebusinessCell Adhesion MoleculesBiomarkersOxidative stress
researchProduct

The Impact of Coconut Oil and Epigallocatechin Gallate on the Levels of IL-6, Anxiety and Disability in Multiple Sclerosis Patients

2020

Background: Due to the inflammatory nature of multiple sclerosis (MS), interleukin 6 (IL-6) is high in blood levels, and it also increases the levels of anxiety related to functional disability. Epigallocatechin gallate (EGCG) decreases IL-6, which could be enhanced by the anti-inflammatory effect of high ketone bodies after administering coconut oil (both of which are an anxiolytic). Therefore, the aim of this study was to assess the impact of coconut oil and EGCG on the levels of IL-6, anxiety and functional disability in patients with MS. Methods: A pilot study was conducted for four months with 51 MS patients who were randomly divided into an intervention group and a control group. The …

Male0301 basic medicineTime FactorsMediterranean dietEmotionsPilot ProjectsEpigallocatechin gallateDiet Mediterraneanmultiple sclerosisGastroenterologyCatechinBody Mass IndexDisability Evaluationchemistry.chemical_compound0302 clinical medicineProspective Studiescoconut oilNutrition and DieteticsCoconut oilfood and beveragesMiddle AgedMultiple Sclerosis Chronic ProgressiveanxietyTreatment OutcomeAnxietyFemalemedicine.symptomlcsh:Nutrition. Foods and food supplyepigallocatechin gallatemedicine.medical_specialtyfood.ingredientmedicine.drug_classlcsh:TX341-641PlaceboAnxiolyticArticle03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingfoodInternal medicinemedicineHumansExpanded Disability Status Scalebusiness.industryinterleukin-6Recovery of Function030104 developmental biologydisabilitychemistrySpainDietary SupplementsbusinessBody mass indexBiomarkers030217 neurology & neurosurgeryFood ScienceNutrients
researchProduct

Mean Platelet Volume and Arterial Stiffness - Clinical Relationship and Common Genetic Variability

2017

AbstractVessel wall stiffening is an important clinical parameter, but it is unknown whether platelets, key elements in the pathogenesis of arterial thrombosis, are associated with arterial stiffness. The present studies sought to determine whether mean platelet volume (MPV), a potential marker of platelet activation, is linked to vascular elasticity as assessed by the augmentation index (AIx), in 15,010 individuals from the population-based Gutenberg Health Study. Multivariable analysis showed that MPV in both males (β 0.776; 95thCI [0.250;1.16]; p = 0.0024) and females (β 0.881[0.328;1.43]; p = 0.0018) is strongly associated with AIx. Individuals with MPV and AIx above the sex-specific me…

Male0301 basic medicinemedicine.medical_specialtyPopulationKaplan-Meier Estimate030204 cardiovascular system & hematologyPolymorphism Single NucleotideArticle03 medical and health sciencesSex FactorsVascular Stiffness0302 clinical medicineGUTENBERG HEALTHDEFICIENTINFLAMMATIONRisk FactorsInternal medicinemedicineHumansPlateletPlatelet activationMean platelet volumeeducationMETAANALYSISeducation.field_of_studyMultidisciplinaryHYPERTENSIONbusiness.industryProportional hazards modelHazard ratioGenetic VariationCROSS-SECTIONAL RELATIONSmedicine.diseaseThrombosisElasticityREACTIVITY030104 developmental biologyISCHEMIC-STROKEATHEROSCLEROSISCardiovascular DiseasesArterial stiffnessCardiologyFemalebusinessMean Platelet VolumeVASCULAR FUNCTIONBiomarkers
researchProduct

Effect of High‐Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis

2019

International audience; Objective: Weight loss has been identified as a negative prognostic factor in amyotrophic lateral sclerosis, but there is no evidence regarding whether a high-caloric diet increases survival. Therefore, we sought to evaluate the efficacy of a high-caloric fatty diet (HCFD) for increasing survival.Methods: A 1:1 randomized, placebo-controlled, parallel-group, double-blinded trial (LIPCAL-ALS study) was conducted between February 2015 and September 2018. Patients were followed up at 3, 6, 9, 12, 15, and 18 months after randomization. The study was performed at 12 sites of the clinical and scientific network of German motor neuron disease centers (ALS/MND-NET). Eligible…

Male0301 basic medicinemortality [Amyotrophic Lateral Sclerosis]MESH: Combined Modality Therapy[SDV]Life Sciences [q-bio]law.invention0302 clinical medicineMESH: RiluzoleRandomized controlled triallawdiet therapy [Amyotrophic Lateral Sclerosis]Clinical endpointMedicineMESH: Double-Blind Methodtherapeutic use [Riluzole]MESH: Amyotrophic Lateral Sclerosismethods [Combined Modality Therapy]education.field_of_studyRiluzoleMESH: Middle AgedHazard ratioMESH: Neuroprotective AgentsMiddle Agedtherapeutic use [Neuroprotective Agents]Combined Modality Therapy3. Good healthRiluzole[SDV] Life Sciences [q-bio]Neuroprotective AgentsNeurologyMESH: Survival AnalysisFemalemedicine.drugmortality [Diet High-Fat]medicine.medical_specialtyPopulationDiet High-FatPlacebo03 medical and health sciencesDouble-Blind MethodInternal medicineHumansddc:610educationSurvival analysisMESH: Humansdrug therapy [Amyotrophic Lateral Sclerosis]business.industryAmyotrophic Lateral SclerosisSurvival AnalysisConfidence intervalMESH: MaleMESH: Diet High-Fat030104 developmental biologyNeurology (clinical)businessMESH: Female030217 neurology & neurosurgery
researchProduct

Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines…

2016

Palmitoylethanolamide (PEA) is an endogenous lipid mediator known to reduce pain and inflammation. However, only limited clinical studies have evaluated the effects of PEA in neuroinflammatory and neurodegenerative diseases. Multiple sclerosis (MS) is a chronic autoimmune and inflammatory disease of the central nervous system. Although subcutaneous administration of interferon (IFN)-β1a is approved as first-line therapy for the treatment of relapsing–remitting MS (RR-MS), its commonly reported adverse events (AEs) such as pain, myalgia, and erythema at the injection site, deeply affect the quality of life (QoL) of patients with MS. In this randomized, double-blind, placebo-controlled study,…

Male0301 basic medicinemyalgiaErythemaAnti-Inflammatory AgentsPalmitic AcidAdministration OralPharmacologyGastroenterologychemistry.chemical_compound0302 clinical medicineNeuroinflammationFAAHEthanolaminePharmacology (medical)SkinInterleukin-17food and beveragesAnti-Inflammatory AgentTolerabilityEthanolaminesDisease ProgressionCytokinesOriginal ArticleFemalemedicine.symptomInterferon beta-1aHumanAdultmedicine.medical_specialtyPainPalmitic AcidsProinflammatory cytokineInterferon-gamma03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingDouble-Blind MethodInternal medicinemedicineHumansAdverse effectCytokinePharmacologyPalmitoylethanolamideExpanded Disability Status ScaleTumor Necrosis Factor-alphabusiness.industryMultiple sclerosisN-acylethanolamineOleoylethanolamideAnandamideNAAAmedicine.diseaseAmides030104 developmental biologychemistryNeurology (clinical)business030217 neurology & neurosurgeryNeurotherapeutics
researchProduct

Early high-dosage atorvastatin treatment improved serum immune-inflammatory markers and functional outcome in acute ischemic strokes classified as la…

2016

Statins have beneficial effects on cerebral circulation and brain parenchyma during ischemic stroke and reperfusion. The primary hypothesis of this randomized parallel trial was that treatment with 80 mg/day of atorvastatin administered early at admission after acute atherosclerotic ischemic stroke could reduce serum levels of markers of immune-inflammatory activation of the acute phase and that this immune-inflammatory modulation could have a possible effect on prognosis of ischemic stroke evaluated by some outcome indicators. We enrolled 42 patients with acute ischemic stroke classified as large arteries atherosclerosis stroke (LAAS) randomly assigned in a randomized parallel trial to the…

Male3400P-selectinAtorvastatinInterleukin-1beta030204 cardiovascular system & hematologylaw.inventionBrain IschemiaBrain ischemiaCerebral circulation0302 clinical medicineRandomized controlled triallawAtorvastatinIntracranial ArteriosclerosiStrokeInflammation MediatorbiologyClinical Trial/Experimental StudyGeneral MedicineMiddle AgedIntracranial ArteriosclerosisIntercellular Adhesion Molecule-1Interleukin-10StrokeP-SelectinAcute DiseaseCardiologyFemaleInflammation Mediatorsmedicine.symptomE-SelectinResearch Articlemedicine.drugHumanmedicine.medical_specialtyVascular Cell Adhesion Molecule-1Inflammation03 medical and health sciencesInternal medicinemedicineHumanscardiovascular diseasesInterleukin 6AgedInflammationbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaBiomarkermedicine.diseasePhysical therapybiology.proteinbusinessBiomarkers030217 neurology & neurosurgery
researchProduct

“Better explanations” in multiple sclerosis diagnostic workup

2019

BackgroundThe exclusion of other diseases that can mimic multiple sclerosis (MS) is the cornerstone of current diagnostic criteria. However, data on the frequency of MS mimics in real life are incomplete.MethodsA total of 695 patients presenting with symptoms suggestive of MS in any of the 22 RIREMS centers underwent a detailed diagnostic workup, including a brain and spinal cord MRI scan, CSF and blood examinations, and a 3-year clinical and radiologic follow-up.FindingsA total of 667 patients completed the study. Alternative diagnoses were formulated in 163 (24.4%) cases, the most frequent being nonspecific neurologic symptoms in association with atypical MRI lesions of suspected vascular…

Male404241Longitudinal StudieDisease0302 clinical medicineMultiple SclerosiDiagnosisMedicine030212 general & internal medicineProspective StudiesLongitudinal StudiesProspective cohort studymedicine.diagnostic_testMagnetic Resonance Imagingclinical practiceatypical MRI lesionsMS mimicsDisease ProgressionFemaleSettore MED/26 - NeurologiaRadiologyHumanAdultmultiple sclerosis; diagnostic criteria; atypical MRI lesions; MS mimics; clinical practicemedicine.medical_specialtyMultiple Sclerosis2omarkers / metabolism Diagnosis Differential Female Follow-Up Studies Humans Longitudinal Studies Magnetic Resonance Imaging Male Multiple Sclerosis / diagnosis* Prospective StudiesArticleFollow-Up StudieDiagnosis Differential03 medical and health sciencesHumansNeuromyelitis opticabusiness.industryMultiple sclerosisAdult; Biomarkers; Diagnosis Differential; Female; Follow-Up Studies; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Prospective StudiesMagnetic resonance imagingOdds ratioBiomarkermedicine.disease101MigraineDifferentialdiagnostic criteriaNeurology (clinical)Differential diagnosisbusiness030217 neurology & neurosurgeryBiomarkersFollow-Up StudiesNeurology
researchProduct